Phase 1 Study of HS-20152 in Healthy Participants

Summary

This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study will evaluate the safety and tolerability of HS-20152, an investigational therapy targeting the complement pathway, in healthy adults. Secondary objectives include characterization of pharmacokinetics and pharmacodynamic effects on complement-related biomarkers.

Timeline

Start

2026-04-22

Primary completion

2027-01-01

Completion

2027-07-01

Drugs

Indications

No indication recorded.